Literature DB >> 6166003

Inhibition of vaccinia mRNA methylation by 2',5'-linked oligo(adenylic acid) triphosphate.

O K Sharma, B B Goswami.   

Abstract

Extracts of interferon-treated cells synthesize unique 2',5'-linked oligo(adenylic acid) 5'-phosphates in the presence of ATP and double-stranded RNA. 2',5'-linked oligo(adenylic acid) 5'-triphosphate inhibits protein synthesis at nanomolar concentrations by activating RNase. We have observed that oligo(adenylic acid) 5'-monophosphate and 5'-triphosphate are potent inhibitors of vaccinia mRNA methylation in vitro. Both the methylation of mRNA methylation is not due to degradation of the mRNA. Inhibition of the 5'-terminal guanine at the 7 position and the 2'-O-ribose methylation of the penultimate nucleoside are inhibited. Such inhibition of the requisite modification of the 5' terminus of mRNA by 2',5'-linked oligo(adenylic acids) may be a mechanism of interferon action against both DNA and RNA viruses in which mRNAs derived from them are capped.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166003      PMCID: PMC319316          DOI: 10.1073/pnas.78.4.2221

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis.

Authors:  W K Roberts; A Hovanessian; R E Brown; M J Clemens; I M Kerr
Journal:  Nature       Date:  1976-12-02       Impact factor: 49.962

2.  Capping of eucaryotic mRNAs.

Authors:  A J Shatkin
Journal:  Cell       Date:  1976-12       Impact factor: 41.582

3.  Limitation of reticulocyte transfer RNA in the translation of heterologous messenger RNAs.

Authors:  O K Sharma; D N Beezley; W K Roberts
Journal:  Biochemistry       Date:  1976-09-21       Impact factor: 3.162

4.  Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells.

Authors:  A Zilberstein; P Federman; L Shulman; M Revel
Journal:  FEBS Lett       Date:  1976-09-15       Impact factor: 4.124

5.  Natural occurrence of 2-5A in interferon-treated EMC virus-infected L cells.

Authors:  B R Williams; R R Golgher; R E Brown; C S Gilbert; I M Kerr
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

6.  Methylated 5'-terminal sequences of vaccinia virus mRNA species made in vivo at early and late times after infection.

Authors:  R F Boone; B Moss
Journal:  Virology       Date:  1977-06-01       Impact factor: 3.616

7.  Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis.

Authors:  P J Farrell; K Balkow; T Hunt; R J Jackson; H Trachsel
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

8.  5'-Terminal structure and mRNA stability.

Authors:  Y Furuichi; A LaFiandra; A J Shatkin
Journal:  Nature       Date:  1977-03-17       Impact factor: 49.962

9.  Impairment of reovirus mRNA methylation in extracts of interferon-treated Ehrilich ascites tumor cells: further characteristics of the phenomenon.

Authors:  G C Sen; S Shaila; B Lebleu; G E Brown; R C Desrosiers; P Lengyel
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

10.  The effect of interferon on the formation of virus polyribosomes in L cells infected with vaccinia virus.

Authors:  D H Metz; M Esteban; G Danielescu
Journal:  J Gen Virol       Date:  1975-05       Impact factor: 3.891

View more
  3 in total

1.  2-5A accumulates to high levels in interferon-treated, vaccinia virus-infected cells in the absence of any inhibition of virus replication.

Authors:  A P Rice; W K Roberts; I M Kerr
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

2.  Inhibition of vaccinia virus growth and virus-specific RNA synthesis by 3'-O-methyl adenosine and 3'-O-methyl guanosine.

Authors:  B B Goswami; O K Sharma
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

Review 3.  The viral RNA capping machinery as a target for antiviral drugs.

Authors:  François Ferron; Etienne Decroly; Barbara Selisko; Bruno Canard
Journal:  Antiviral Res       Date:  2012-07-26       Impact factor: 5.970

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.